Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™ [Globe and Mail, The (Toronto, Canada)]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Globe and Mail, The
MONTREAL Dec. 13, 2024 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of PLUVICTO™ (lutetium (177Lu) vipivotide tetraxetan injection). While this is an important milestone, patients do not yet have public access through provincial and territorial formularies. We look forward to timely collaboration with participating jurisdictions to ensure that eligible prostate cancer patients that are urgently awaiting treatment will have access without further delay. "This agreement represents a transformative milestone for Canadian men facing advanced prostate cancer," said Laurent Proulx , President and CEO of PROCURE. "It is a remarkable achievement and a testament to how advancements in science are enabling patients to live longer and improve their quality of life, ensuring that no eligible patient is left behind." Dr. Ricardo Rendon ,
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]Yahoo! Finance
- Sandoz Boss Warns There's a Climate Cost of Obesity Wonder Drugs [Yahoo! Finance]Yahoo! Finance
- Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing [Yahoo! Finance]Yahoo! Finance
- Novartis AG (NVS): Among the Oversold Global Stocks to Buy Right Now [Yahoo! Finance]Yahoo! Finance
- NVS vs. LLY: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 10/29/24 - Beat
NVS
Sec Filings
- 11/25/24 - Form 6-K
- 10/29/24 - Form 6-K
- 10/29/24 - Form 6-K
- NVS's page on the SEC website